NorthWest Biotherapeutics Inc (NWBO)

[austinmediainc]

The PR only says he will be discussing the information arm, nothing else in the 15 minutes he is presenting. Was the abstract tied to this conference?

During his presentation, Dr. Bosch will discuss data relating to 51 patients with Glioblastoma multiforme (GBM) brain cancer who were treated with DCVax-L on a compassionate basis in an "Information Arm" outside of the Company's Phase III clinical trial. These patients were not eligible for the clinical trial because they were already showing some actual or apparent re-growth of their brain tumor in imaging at a Baseline Visit when they finished 6 weeks of daily radiotherapy and chemotherapy following the surgical removal of their original tumor as part of the standard of care. Such patients are considered either "rapid progressors" or "pseudo-progressors," based upon whether the appearance of early tumor re-growth can be subsequently confirmed. Dr. Bosch will discuss survival data relating to such patients.